Carvykti's success boosts Legend Biotech Corporation's Q4 2024 sales to $334M, solidifying market position. Click to find out ...

Legend Biotech is building a new $150 million manufacturing plant, with its partner Johnson & Johnson, with the goal of ...

Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

Unlocking manufacturing capacity will be key for Legend Biotech and Johnson and Johnson in achieving their goal of reaching ...

Legend Biotech’s (LEGN) shares have surged over 10% in the past few days, spurred by the company’s latest earnings report, thanks to ...

Legend Biotech Corp (LEGN) reports a 110% increase in CARVYKTI sales, outlines expansion strategies, and anticipates ...

This comprehensive analysis examines Legend Biotech's strengths, challenges, and market position, providing insights into the factors that could shape its trajectory in the coming years. Carvykti ...

Q4 2024 Earnings Call Transcript March 11, 2025 Legend Biotech Corporation beats earnings expectations. Reported EPS is $0.08 ...

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 ...

Legend Biotech, a leader in cell therapy, has achieved significant milestones in its fourth quarter of 2024 performance. The ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

There are more milestones ahead that will potentially make CARVYKTI available to even more patients,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “CARVYKTI has already ...